Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 16/20 | 0.50 |
| ▸ | TDO2 | P48775 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2516716 | 1.00 | IDO1 (0.50) | IDO1TDO2MAPTPOLBHPGD | |
| SCHEMBL2516714 | 1.00 | IDO1 (0.50) | IDO1TDO2MAPTPOLBHPGD | |
| SCHEMBL2520514 | 0.88 | IDO1 (0.53) | IDO1TDO2MAPTPOLBHPGD | |
| SCHEMBL30449075 | 0.88 | IDO1 (0.61) | IDO1TDO2MAPTHTTLMNA | |
| SCHEMBL29627125 | 0.88 | IDO1 (0.61) | IDO1TDO2MAPTHTTLMNA | |
| SCHEMBL16706552 | 0.88 | IDO1 (0.62) | IDO1TDO2POLBHPGD | |
| SCHEMBL2512653 | 0.88 | IDO1 (0.47) | IDO1TDO2MAPTPOLBHPGD | |
| SCHEMBL2512651 | 0.88 | IDO1 (0.47) | IDO1TDO2MAPTPOLBHPGD | |
| SCHEMBL149916 | 0.88 | IDO1 (0.62) | IDO1TDO2POLBHPGD | |
| SCHEMBL149780 | 0.88 | IDO1 (0.61) | IDO1TDO2MAPTHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885MAPT 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.